Newark

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• HIV6 trials
• Asthma1 trial
• Cytomegalovirus infection1 trial

Phase

• Phase 23 trials
• Phase 33 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting4 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• ViiV Healthcare6 trials
• GlaxoSmithKline2 trials

Running trials

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

  Contact: Jihad Slim (principal investigator)

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

  Contact: Jihad Slim (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

  NCT06694805· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

  NCT06372496· Phase 4· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

  NCT05996471· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV2 recruiting

Closed trials

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· ViiV Healthcare· Source

• Completed

  A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

  NCT05089630· Phase 1/2· GlaxoSmithKline· Source